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Background: This study evaluated the factors and costs associated with discharge destination and
readmission, within 90 days of surgery, for primary or revision total knee arthroplasty (TKA) and total hip
arthroplasty (THA).
Methods: This retrospective database analysis used health care claims from the Truven MarketScan
Database (2009-2013). Patients were selected if aged 18 years, with continuous health plan enrollment
from 3-month baseline through 3-month follow-up. Logistic regression and Cox proportional hazard
models were used to analyze factors associated with discharge destination and risk of readmission. Total
90-day costs were calculated for different patient pathways of care, dependent on complications,
discharge destination, and readmission status.
Results: A total of 323,803 primary TKA, 25,354 revision TKA, 159,390 primary THA, and 17,934 revision
THA cases met selection criteria. All-cause complications occurred in 2.5%, 37.2%, 2.6%, and 35.0% of each
cohort. Complications, transfusions, and length of stay 3 days were associated with greater odds of
discharge to home with home health services or skilled nursing facility (SNF) vs home under self-care
(P < .001 all cohorts), whereas discharge to home with home health services or SNF was associated
with greater risk of readmission (P < .05 for all cohorts except one). The ratio of total 90-day costs for the
highest- (revision, SNF, readmission) vs lowest-cost (primary, home under self-care, no readmission) care
pathways ranged from 1.8 to 2.2.
Conclusion: As Medicare payment policy for total joint arthroplasty shifts toward bundling, an awareness
of factors associated with outlier costs will be requisite to remain proﬁtable.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The incidence of total knee arthroplasty (TKA) in the United
States is rising and has been projected to increase from 500,000
procedures in 2005 to 3.48 million in 2030 [1]. Not only is the
demand for total joint arthroplasty (TJA) procedures rising, but a
recent model using US Census, National Health Expenditures, and
Nationwide Inpatient Sample data found that growth in both pri-
mary and revision TKA procedures was insensitive to the economic
downturn, with growth of 6.1% and 13.5% between 2009 and 2010,
respectively [2].
Against this backdrop of increasing procedural volume, Centers
for Medicare and Medicaid Services has been tasked with costclosed potential or pertinent
ent, either direct or indirect,
the biomedical ﬁeld which
rest with this work. For full
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Advanced Energy, 180 Inter-
Inc. This is an open access article ucontainment under the Affordable Care Act. Speciﬁcally targeted is
diagnosis related group (DRG) 470, the reimbursement code used
to classify hip and knee arthroplasty procedures without major
complications or comorbidity. As the single-most commonly billed
DRG code, it totaled $6.6 billion in Medicare payments in 2013
alone and is consequently a prime target for innovative value-based
payment programs [3].
One such program is the Medicare Bundled Payment for Care
Improvement initiative, which revises Medicare payment policy to
align hospital incentives around coordinated care from the initial
hospitalization through the 90-day care period after discharge. This
voluntary program combines previously separate, fee-for-service
payments for all hospital and post-discharge care costs into a sin-
gle, prospective payment that is managed by the hospital. Although
the speciﬁcs of bundling models vary, the overall purpose is to
provide strong ﬁnancial incentives for caregivers and hospitals to
manage episode costs [4]. More recently, the Comprehensive
Care for Joint Replacement (CJR) model will require all hospitals innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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program starting April 1, 2016 [5].
Hospitals enrolled in a bundled payment program simulta-
neously face large upside potential and signiﬁcant downside risk.
Hospital-speciﬁc bundled payments are calculated using the mean
of three years of historical Medicare payment data to adjust for
variations in casemix and cost. However, just a few high-cost out-
liers per year can eliminate or signiﬁcantly reduce the hospital's
margin on performing joint arthroplasty surgery. For example, as
discussed in a recent New England Journal of Medicine opinion
article, though Medicare paid an average of $26,000 per 90-day
episode for DRG 470 in 2013, the top percentile (1%) of TJAs cost
$75,000 per episode [6]. Because of the potential impact of this
difference on annual operating margin, some hospitals rely on
“stopgap” insurance to minimize downside risk; however, this
additional cost layer further cuts into potential proﬁts. Ideally,
clinical strategies to optimize outcomes across all demographics
groups, mitigating cost outliers and reducing variability in patient
costs over the entire episode of care, are essential in this new
payment environment.
Post-discharge costs, including the cost of readmissions, are one
of the largest drivers of the total 90-day cost of care; one estimate
found that the initial hospitalization accounted for only 55% of total
episode costs [6]. Thus, optimized strategies to minimize poste
acute care (PAC) costs, while not compromising patient clinical
outcomes, are warranted. However, there has been little research
on ideal care pathways after TJA. In an analysis of a single center's
administrative claims database, authors evaluated over 1800 pri-
mary TJA procedures and found that the average 30-day post-
discharge cost varied widely by surgeon, from $733 to $12,811 [7].
This suggests that there is at least some surgeon preference toward
PAC setting rather than adherence to any predeﬁned care pathways.
Although the trend of discharging more patients to home with
home health services (HHHS) care instead of skilled nursing facil-
ities (SNF) has increased signiﬁcantly, from 15% to 35% between
1998 and 2009 [8], there has been little research on the clinical
drivers and outcomes associated with this shift.
Cost containment is critical to hospitals' long-term ﬁnancial
sustainability; however, it cannot come at the expense of patient
outcomes. Research evaluating the safety and efﬁcacy of different
care pathways is needed to inform the development of cost-
containment strategies. The present study uses nationally repre-
sentative claims data frommore than 500,000 patients undergoing
primary or revision TKA or total hip arthroplasty (THA) procedures
to evaluate costs and clinical outcomes over a 90-day care episode.
Factors associatedwith discharge destinationwere evaluated, along
with the destination's impact on the risk of hospital readmission.
Materials and Methods
This retrospective database analysis used health care claims
data from the MarketScan Commercial Research Database (Truven
Health Analytics, Ann Arbor, MI), which includes nationally repre-
sentative information for >180 million unique patients covered
with private insurance. Data from 2009 through 2013 were used for
this analysis. The database is fully deidentiﬁed; therefore, this study
did not require Institutional Review Board approval. Patients with
Medicare were not excluded from this study but were required to
have some form of supplemental health insurance coverage to be
included in the data set.
Four mutually exclusive study cohorts were created for analysis,
based on relevant International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) or Current Procedural
Terminology (CPT) codes (Appendix A): primary TKA, revision TKA,
primary THA, and revision THA procedures. For the primary TKAand THA cohorts, patients were selected if they had a relevant
procedure code but no multiple listings (indicating bilateral or
concurrent THA or TKA procedures) or revision procedures. Pa-
tients with simultaneous bilateral procedures were excluded from
the present analyses because of the greater operating room and
supply costs when compared to unilateral procedures. Revision TKA
and revision THA cohorts were selected if an ICD-9-CM or CPT
procedure code was listed for a revision procedure. For all study
cohorts, patients were excluded from analysis if there was any
diagnosis of fracture of the lower limb listed during baseline or the
index hospitalization.
Patients were eligible if aged 18 years, with continuous health
plan enrollment from 3 months before surgery through 3-month
follow-up. Patients who did not survive the index hospitalization
(and therefore had no post-discharge data) were excluded, as were
patients whose 90-day follow-up costs were within the top 1% of
costs. This methodology excluded patients with total 90-day costs
greater than $118,400 for primary TKA, $123,133 for primary THA,
$189,196 for revision TKA, and $195,429 for revision THA, which
given the distribution of cost information observed were extreme
outlier observations likely a result of miscoding.
The “index date” for analysis was the date of hospital admission
for the procedure of interest. The baseline periodwas deﬁned as the
90 days before the index date, and the follow-up period deﬁned as
the day of discharge through 90 days after discharge. The 90-day
follow-up time frame was selected for this analysis because the
majority of hospitals that have opted into the Medicare bundled
payment program chose the 90-day time frame for the bundle, and
this is also the time period for bundling in the Comprehensive Care
for Joint Replacement Program program [3,5].
Patient demographic and clinical characteristics, complications
during the index visit, length of stay (LOS), and costs were analyzed.
Comorbidities were evaluated using diagnoses listed during base-
line, the index hospitalization episode, and during any read-
missions. The Charlson Comorbidity Index (CCI) score, a validated
composite measure of physical health status, was calculated for
each patient using diagnoses listed on a patient's record from a 1-
year baseline through 90-day follow-up [9,10]. Because the data
source had no information on individual patient body mass index,
diagnosis of overweight or obesity was assessed using ICD-9-CM
diagnosis codes (278.00-278.03, V8541, V8542, V8543, V8544,
and V8545).
Diagnosis and procedure codes used in study measure creation
are listed in Appendix B, similar to those used in a prior retro-
spective study with Premier data [11]. Complications of interest
during the index hospitalization included blood transfusion (allo-
geneic or autologous), transfusion-related complications, hemor-
rhage, hematoma, seroma, postoperative infection, wound
disruption, phlebitis and thrombophlebitis, pulmonary embolism,
pneumonia, and any other neurologic, pulmonary, cardiac, or uri-
nary and renal complication. Discharge destination was evaluated
given the information listed in the Premier data set, including home
under self-care (HUSC), HHHS, SNF, or other (including inpatient
rehabilitation, short-term hospital, transferred to other facility,
other).
Costs reported in the Truven data set represent the sum of all
amounts paid to the provider by the insurer plus coinsurance,
copayments, and deductibles paid by the patient for the same visit.
We summarized total hospitalization costs during the index hos-
pitalization, along with total follow-up costs. Follow-up costs were
summed from the day of discharge through 90 days for the
discharge destination plus costs incurred in the following locations:
clinic, ofﬁce, outpatient hospital, outpatient rehabilitation, and
other outpatient. Conditional on presence of a hospital readmission
during follow-up, the total hospitalization cost for the readmission
Table 1
Demographic and Clinical Characteristics.
Primary
Unilateral
TKA
Primary
THA
Revision
TKA
Revision
THA
P
Valuea
N 323,803 159,390 25,354 17,934
Age (mean ± SD) 63.5 ± 9.8 62.5 ± 11.6 63.3 ± 10.5 63.5 ± 12.8 <.001
Age group, %
<65 60.7 62.6 61.3 58.5 <.001
65 to 74 23.6 20.3 22.2 18.7
75 to 84 13.9 14.1 14.0 17.5
85 1.8 3.1 2.5 5.3
Female, % 61.2 53.8 57.7 54.8 <.001
Residence, %
Northeast 17.9 28.9 18.0 27.8 .004
South 34.1 21.9 33.4 19.8
Midwest 31.3 29.9 31.7 32.3
West 16.8 19.3 16.8 20.1
Charlson Score
(mean ± SD)
0.89 ± 1.23 0.83 ± 1.28 1.15 ± 1.49 1.09 ± 1.51 <.001
Charlson Score
breakout, %
<.001
0 50.7 56.2 44.2 48.2
1 26.7 23.1 26.7 24.2
2 13.0 11.5 14.4 13.7
3 9.6 9.2 14.7 13.9
Top Charlson comorbidities, %
C.I. Nichols, J.G. Vose / The Journal of Arthroplasty 31 (2016) 1400e14061402was summarized. Finally, incremental 90-day costs were calculated
as the difference in the total 90-day cost for patients discharge to
HHHS vs HUSC and for patients discharged to an SNF vs HUSC. All
costs were inﬂation adjusted to 2013 USD using the medical care
component of the consumer price index.
Descriptive analyses include mean, median, and standard de-
viation values for continuous measures and proportions for binary
measures. Statistical signiﬁcance testing compared outcomes be-
tween patients with primary vs revision procedures, using the chi-
square test for categorical variables and t test orWilcoxon rank-sum
test for continuous variables. Multivariate logistic regression
models were constructed to evaluate predictors of discharge
destination to locations other than HUSC; covariates were patient
age, gender, geographic region, presence of an overweight or
obesity diagnosis, the CCI score, presence of an all-cause compli-
cation or transfusion during the index hospitalization, and index
hospitalization LOS. Cox proportional hazard models were used to
evaluate factors associated with increased risk of hospital read-
mission within 90 days, using the aforementioned covariates and
discharge destination from the index hospitalization. All analyses
were performed using the Instant Health Data Suite (Boston Health
Economics, Inc, Waltham, MA) and SAS software (version 9.2, SAS
Institute, Cary, NC) packages.Diabetes without
complications
22.9 15.8 26.4 17.4 <.001
Diabetes with
complications
3.6 2.5 5.2 3.4 <.001
Chronic
pulmonary
disease
16.5 15.4 19.2 18.6 <.001
Rheumatologic
disease
4.8 4.5 6.4 7.1 <.001
Renal disease 4.7 4.5 7.6 6.8 <.001
Congestive heart
failure
3.7 3.9 6.8 6.7 <.001
Obese or
overweightb
22.1 16.4 22.1 14.4 <.001
SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty.
a P values: primary vs revision cohorts, t test for continuous variables, chi square
for proportions.
b Indicated by an International Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation diagnosis for overweight/obesity. No body mass index information
was available in this data set.Results
Between January 1, 2009 and December 31, 2013, a total of
526,481 patients met selection criteria. Of those, 323,803 (61.5%)
were primary unilateral TKA, 159,390 (30.3%) were primary uni-
lateral THA, 25,354 (4.8%) were revision TKA, and 17,934 (3.4%)
were revision THA procedures.
Demographic and clinical characteristics are summarized in
Table 1. The mean age was 63 years and was similar across cohorts,
with the majority of patients in all cohorts female. The CCI score
was greater in the revision TKA and THA cohorts (1.15 ± 1.49 and
1.09 ± 1.51, respectively) vs the primary TKA and THA cohorts (0.89
± 1.23 and 0.83 ± 1.28, respectively, P < .001); similarly, the pro-
portion with a high CCI score (3) was greater in the revision than
in the primary cohorts (14.7% and 13.9% vs 9.6% and 9.2%, P < .001).
The most common comorbidities comprising the CCI scores in all
cohorts were diabetes without complications, chronic pulmonary
disease, renal disease, congestive heart failure, and rheumatologic
disease. Slightly fewer primary and revision THA patients were
overweight or obese (16.4% and 14.4%) compared to primary and
revision TKA patients (22.1% for each cohort, respectively, P < .001).
Characteristics associated with the index admission are sum-
marized in Table 2. During the index hospitalization, the incidence
of transfusion was greater for revision procedures (revision TKA:
8.4% and THA: 15.9%) vs primary procedures (primary TKA: 6.8%
and THA: 10.1%, P < .001). Presence of any complication was lower
for the primary procedures (primary TKA: 2.5% and THA: 2.6%) vs
the revision procedures (revision TKA: 37.2% and THA: 35.0%, P <
.001). The most prevalent complications during the index visit lis-
ted for primary procedures were pulmonary complications (0.7%
for both primary cohorts) or pneumonia (0.7% for both primary
cohorts). For revision procedures, themost prevalent complications
were postoperative infection (24.1% for TKA and 16.0% for THA),
wound disruption (1.7% for TKA and 1.3% for THA) and hemorrhage,
hematoma, or seroma (1.5% for revision TKA and 2.2% for revision
THA). Mean LOSs for the primary TKA and THA cohorts (4.8 ± 3.9
and 4.7 ± 4.2 days, respectively) were shorter than for the revision
TKA and THA cohorts (5.6 ± 7.2 and 6.3 ± 8.7 days, respectively, P <
.001). In all cohorts, the majority (68.9%-76.8%) of patients had an
LOS of >3 days.Discharge destination after the index hospitalization is sum-
marized in Table 2. In each cohort, the majority of patients were
discharged to HUSC (38%-41%), followed by HHHSs (34%-39%). The
proportion of patients discharged to an SNF increased with a longer
LOS during the index hospitalization. Less than 1% of patients
staying <3 days were discharged to an SNF, compared to 17%-21% of
patients staying >3 days.
Incidence and time to readmission within 90 days of discharge
from the index hospitalization are summarized in Table 3. Post-
operative infection was the most frequently listed complication for
hospital readmission in all cohorts, present in 7.0% of primary TKA
and 8.5% of THA readmissions, and 35.6% of revision TKAs and 22.4%
of THAs. Wound disruption and hemorrhage, hematoma, or seroma
were the next-most frequent complications listed during a read-
mission visit for all study cohorts, occurring in 1.6%-5.7% of all
patients.
Readmissions were then stratiﬁed by index LOS and discharge
destination (Table 3). The proportion of patients readmitted within
90 days of discharge was greater for patients that stayed >3 days
during the index visit (ranging from 16% to 27% readmitted) vs
patients staying <3 days (readmissions ranging from 12% to 16%; P
< .001 for all comparisons of discharge destination within each
cohort by LOS). When analyzed according to discharge destination,
Table 3
Readmissions Within 90 Days of Index Admission.
Primary
Unilateral
TKA
Primary
THA
Revision
TKA
Revision
THA
P
Valuea
Sample size (N) 323,803 159,390 25,354 17,934
Any readmission
within 90 days, %
14.8 14.0 23.1 21.7 <.001
Time to readmission (d)
Mean ± SD 29.6 ± 27.6 29.2 ± 27.4 35.5 ± 27.9 29.9 ± 26.5 <.001
Median 19 19 29 20
IQR 5-50 5-49 8-59 7-49
Readmissions by index length of stay, %
<3 d 15.3 12.2 14.8 16.3
3 d 10.9 9.0 12.2 13.2
> 3 d 15.8 16.0 26.5 24.2
Readmissions by discharge destination, %
Home under
self-care
13.1 11.8 19.0 17.8
Home with home
health services
11.6 10.0 19.7 16.9
Skilled nursing
facility
22.0 23.0 34.4 31.3
SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty;
IQR, interquartile range.
a P value: revision cohorts together vs primary cohorts together, Wilcoxon rank-
sum test for continuous variables, chi square for proportions.
Table 2
Characteristics of Index Hospitalization and Discharge Destination.
Primary
Unilateral
TKA
Primary
THA
Revision
TKA
Revision
THA
P
Valuea
Sample size (N) 323,803 159,390 25,354 17,934
Any transfusion (%) 6.8 10.1 8.4 15.9 <.001
Allogeneic 5.9 8.9 7.9 15.1 <.001
Autologous 1.1 1.4 0.5 1.1 <.001
Any complication (%) 2.5 2.6 37.2 35.0 <.001
Postoperative infection 0.6 0.5 24.1 16.0 <.001
Wound disruption 0.3 0.1 1.7 1.3 <.001
Hemorrhage, hematoma,
or seroma
0.5 0.6 1.5 2.2 <.001
Pulmonary 0.7 0.7 1.3 1.8 <.001
Pneumonia 0.7 0.7 1.2 1.3 <.001
Neurologic 0.6 0.8 0.6 0.2 .026
Cardiac 0.5 0.4 0.3 0.7 .581
Phlebitis and
thrombophlebitis
0.2 0.1 0.2 0.2 <.001
Urinary and renal 0.3 0.3 0.2 0.2 .009
Transfusion-related
complication
0.1 0.1 0.1 0.3 .007
Pulmonary embolism 0.1 0.1 0.1 0.1 .528
Length of stay, d
Mean 4.8 4.7 5.6 6.3 <.001
SD 3.9 4.2 7.2 8.7
25th Percentile 4.0 3.0 4.0 4.0
Median 4.0 4.0 4.0 4.0
75th Percentile 5.0 4.0 5.0 6.0
Length of stay group (%) <.001
<3 d 3.7 6.2 4.8 3.8
3 d 19.5 24.9 19.5 20.1
>3 d 76.8 68.9 75.7 76.1
Discharge destination (%)
Home under self-care 40.2 39.6 40.6 38.1 .141
Home health
organization
36.6 38.5 37.3 34.3 <.001
Skilled nursing facility 14.0 13.8 13.4 16.3 <.001
Otherb 9.3 8.1 8.8 11.3 <.001
SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty.
a P value: revision cohorts together vs primary cohorts together, Wilcoxon rank-
sum test for continuous variables, chi square for proportions.
b Other: inpatient rehabilitation, short-term hospital, transferred to other facility,
other.
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among those discharged to an SNF, followed by HUSC and HHHSs.
Depending on the cohort, 9%-15% more patients were readmitted
among those discharged to an SNF vs HUSC (P < .001 for all com-
parisons of discharge destination within each cohort, by discharge
destination). For all cohorts except revision TKA, slightly more pa-
tients discharged to HUSC vs HHHSs were readmitted within 90
days (1.0%-1.8% difference).
Total 90-day follow-up costs (from day of discharge through 90
days, including costs of the discharge destination and all outpatient
visits) were lowest for patients discharged to HUSC and greatest for
patients discharged to a SNF (Fig. 1). Speciﬁcally, the incremental
increase in the 90-day cost for patients discharged to HHHS vs
HUSC was $978, $1,799, $1,044, and $1,587 for the primary TKA,
revision TKA, primary THA, and revision THA cohorts respectively
(P < .001 within each cohort for total 90-day cost comparison of
HHHS vs HUSC). Incremental increases in the 90-day cost for pa-
tients discharged to an SNF vs HUSC were $3,189, $6,998, $4,486,
and $8,365 for each cohort, respectively (P < .001 within each
cohort for total 90-day cost comparison of SNF vs. HUSC). Among
readmitted patients, mean readmission costs ranged from $9,753
among those with primary TKA to $16,186 among those with a
revision TKA.
In logistic regressionmodels, controlling for patient age, gender,
region, and comorbid diagnoses, patients with any complicationduring the index hospitalization were at signiﬁcantly higher odds
of discharge to an SNF or HHHS vs HUSC. Odds ratios ranged from
1.20 to 1.32 depending on the study cohort (P < .001 for all com-
parisons). Controlling for the same characteristics, patients with a
transfusion procedure during the index visit were also at signiﬁ-
cantly greater odds of discharge to an SNF or HHHS vs HUSC
(odds ratios ranging from 1.69 to 1.99, all P < .001). Furthermore,
patients with an index LOS of 3 days were at signiﬁcantly greater
odds of being discharged to a location other than HUSC vs patients
with a stay of <3 days, with odds ratios ranging from 1.33 to 3.36 for
each study cohort, all P < .001.
Based on the available data, decision trees outlining care path-
ways with cost results for the lowest- and highest-cost scenarios
were constructed (Fig. 2). The lowest-cost scenarios included pa-
tients with a CCI of 0 (ie, no comorbidities), no presence of a
complication or transfusion during the index hospital stay, andwho
were discharged to an HUSC with no readmission within 90 days
(green pathway). The highest-cost scenarios included patients with
a CCI of2 (multiple comorbidities), who either had a complication
or transfusion during the index hospital stay, and who were dis-
charged to a SNF with a subsequent inpatient readmission within
90 days (red pathway). Mean total 90-day costs under the “low-
cost” care pathways ranged from $31,558 to $37,370 for each
patient cohort, whereas mean total 90-day costs under the “high-
cost” care pathways ranged from $48,955 to $80,491. The ratio of
the highest-cost scenario to the lowest-cost scenario was 1.8 times
for the primary TKA cohort, 2.2 for revision TKA, 2.1 for primary
THA, and 2.0 for revision TKA, representing substantial variations in
cost, dependent on the care pathway.Discussion
This retrospective analysis of health care claims data of
>500,000 primary and revision TJA procedures evaluated factors
associated with discharge destination, the impact of discharge
destination on risk of readmission, and total costs for the initial
hospital visit, PAC, and any readmissions within 90 days. The results
showed that, after controlling for patient characteristics and co-
morbid diagnoses, signs of a complication or transfusion during the
Fig. 1. Total 90-day costs by point of care. Follow-up costs (skilled nursing facility, home with home health services, home self-care) were summed from the day of discharge
through 90 days for the discharge destination of interest, plus costs incurred in the following locations: clinic, ofﬁce, outpatient hospital, outpatient rehab, and other outpatient.
Readmission costs were conditional on the presence of a readmission. All costs are inﬂated to 2013 USD using the Medical Care Component of the Consumer Price Index. THA, total
hip arthroplasty; TKA, total knee arthroplasty.
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locations other than HUSC, as was a hospital LOS of 3 days. The
total cost of care in follow-upwas $978 to $1799 greater for patients
discharged to HHHSs care vs HUSC and $3189 to $8365 greater for
patients discharged to an SNF vs HUSC, with speciﬁc costs depen-
dent on the procedure type.
In addition, controlling for patient characteristics, those dis-
charged to an SNF or other point of care (long-term care facilities,
inpatient rehabilitation, or other settings) were at signiﬁcantly
greater risk of readmissionwithin 90 days vs patients discharged to
HUSC. Among readmitted patients, the mean readmission cost
ranged from $9,753 to $16,186, dependent on the procedure type.
When examining the ratio of total 90-day costs for the highest-cost
pathway of care (index visit with complications or transfusion,
discharged to an SNF, and subsequently readmitted) to the lowest-
cost pathway (index visit with no complications or transfusion,
discharged HUSC, no readmission) ratios ranged from 1.8 to 2.2,
representing substantial variations in the total episode cost by the
care pathway.
The majority of literature on the total cost of an episode of care
around TJA focuses on hospital readmissions and predictors of
readmission. However, there are limited studies using large, na-
tionally representative databases on the longitudinal cost of care
including PAC destinations over a 90-day period. In one analysis of
single-center claims data of 1831 primary TKA or THA procedures,
authors summarized average costs in the 30 days after discharge
[7]. Costs were greatest for inpatient rehabilitation ($16,464), fol-
lowed by SNF care ($6,678) and home health care ($4,239) [7].
Discharge directly to home with outpatient therapy had the lowest
total follow-up cost ($733). Although the 30-day follow-up time
period is not directly comparable with our study, the trends in
terms of most-costly points of care after discharge are consistent
with our ﬁndings.
In an analysis of the Medicare 5% ﬁles from 1997 through 2010,
authors found that the most common LOS after a primary TKA or
THA procedure was 3 days, regardless of discharge destination [8].
However, among patients that did stay >3 days, nearly all patients
were discharged to an SNF [8]. This ﬁnding, supported by the re-
sults of our study (69%-77% staying for 3 days), is likely due to the
Medicare “three day rule,” inwhich SNF stays are only covered afteran inpatient stay of at least 3 days. However, in the era of CMS'
Comprehensive Care for Joint Replacement program, the mean
hospital LOS may begin to decrease as the 3-day stay SNF coverage
rule is waived under the bundled payment initiative [5]. Our study
revealed similar ﬁndings, with the odds of discharge to locations
other than HUSC signiﬁcantly greater for patients staying >3 days
during the index hospitalization vs <3 days (odds ratios for
discharge to a location other than HUSC ranging from 2.19 to 3.36
dependent on the study cohort, all P < .001).
Another analysis of 346 hospitals participating in the American
College of Surgeons National Surgical Quality Improvement Pro-
gram data set found that the top three reasons for readmission
within 30 days of primary TJA were surgical site infection (18.8%),
graft or prosthesis complications (7.5%), bleeding (6.3%), and
venous thromboembolism (6.3%) [12]. Similarly, among patients
readmitted in our study, postoperative infection (7.0%-35.6%
dependent on study cohort) and hemorrhage, hematoma or
seroma (ranging from 1.6% to 5.7%) were the top reasons for
readmission. A separate analysis of >2500 patients undergoing
primary or revision TJA found that unplanned readmissions within
30 days were 2.4% for both primary TKA and THA groups, 11.9% for
revision TKA, and 9.5% for revision THA [13]. Authors performed a
detailed analysis of cost and associated breakeven margin, ﬁnding
that hospitals would require 2.8% and 11.9% margins for primary
TKA and revision TKA, respectively, to cover the initial hospitali-
zation episode plus all readmissions if they were to enroll in a
bundled payment system. This ﬁnding that higher readmission
rates after revision procedures place the hospital at greater risk of
a ﬁnancial loss in a bundled payment system corroborates the
results of our study [13].
A separate cost analysis evaluated readmissions by the All Pa-
tient Reﬁned DRG Classiﬁcation System (3M Health Information
Systems, Salt Lake City, UT), which classiﬁes patient morbidity and
mortality according to a proprietary algorithm. Authors found that,
for their center, readmissions after primary TKA and THA pro-
cedures increased with increasing patient All Patient Reﬁned DRG
severity (4.51% readmission rate for patients classiﬁed as minor,
5.24% for major, and 26.09% for patients classiﬁed as extreme) [14].
Our regression analysis of factors associated with readmission
yielded similar ﬁndings, with increasing CCI score signiﬁcantly
Fig. 2. Total 90-day cost, by care pathway. For each pathway, the proportion of patients following each branch is shown for each of the four cohorts analyzed in this study. The
lowest-cost scenario (green pathway) and highest-cost scenario (red pathway) were the same for all 4 cohorts. Total costs for each pathway are shown, by cohort, at the end point.
All-cause complications included postoperative infection, wound disruption, hemorrhage/hematoma/seroma, pneumonia, phlebitis and thrombophlebitis, pulmonary embolism,
urinary and renal, pulmonary, neurologic, cardiac, and transfusion-related complications. Patients could have had both an all-cause complication and a transfusion, if so, they were
included in each pathway in this ﬁgure.
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Other studies have found that prolonged initial hospital LOS, age
>75, body mass index >35, presence of a complication during the
initial visit, Medicare insurance (vs Medicaid or commercial), and
discharge to a SNF vs HHHS or HUSC were all signiﬁcantly associ-
ated with risk of inpatient readmission [15-17]. Speciﬁcally, in a
study of over 27,000 patients undergoing primary hip arthroplasty,
patients discharged directly to an SNF were signiﬁcantly more
likely to be readmitted within 15 days (7.0%) compared to patients
discharged directly HUSC (3.2%) or HHHS (2.7%) [16], which is
consistent with our study ﬁnding that patients discharged to an
SNF were readmitted within 90 days at a signiﬁcantly greater
incidence compared to those discharged to HUSC or HHHSs
(P < .001 for all study cohorts).
Taken together, our results are consistent with existing litera-
ture regarding cost trends by PAC setting and factors associated
with risk of readmission. Most importantly, the PAC destination
appears to add cost to the total episode of care, not only due to the
setting itself, but from increased risk of inpatient readmission
among those discharged to an SNF. As our regression analysis
shows, this is likely due to the correlation between SNF, greater
patient comorbidity status, and a higher likelihood of having
experienced a complication or transfusion during the index hos-
pitalization. Ultimately, this suggests that a subset of cases drive the
top percentiles of costs and, therefore, present the greatest risk of
disrupting a hospital's anticipated margin under a bundled pay-
ment system (Fig. 2). Accordingly, these patients should be subject
to specialized care algorithms from preoperative planning through
discharge to minimize the risk of ﬁnancial losses to the hospital.
This study is subject to the accuracy of health insurance claims
data, whichmay be subject to coding errors and incomplete capture
of patient data. Speciﬁcally, if patients were discharged to a care
facility that was not within the Truven network or were readmitted
to an out-of-network hospital, that care was not necessarily
observed in this analysis. In addition, there are a multitude of
patient-speciﬁc factors associated with discharge location de-
cisions, including the support network available at home, the safety
and layout of the home setting, motivation to continue physical
therapy exercises in an unsupervised setting, and so forth. There-
fore, the clinical-speciﬁc analysis undertaken in the present study is
unable to account for these unobserved, yet important factors in
discharge planning. Nonetheless, strengths of this study include the
large sample size available for analysis and longitudinal nature of
the database which allows for an estimation of total costs over 90
days of care. The results of this study point to trends in discharge
destinations and the subsequent change in total costs, which will
be of help to hospitals shifting to a bundled payment system.
Conclusions
In summary, patients who experienced a complication or
received a transfusion during the index hospitalization were at
signiﬁcantly higher odds of discharge to a PAC setting other than
HUSC, subsequently increasing incremental costs for a 90-day
episode of care. Furthermore, patients discharged to an SNF also
demonstrated signiﬁcantly higher risk of hospital readmission
compared to patients discharged to HUSC. Finally, there appears to
be a beneﬁt in terms of reduced risk of readmission among patientsdischarged to HHHSs vs HUSC (P < .001 for all cohorts except
revision TKA in unadjusted and adjusted results). These ﬁndings
may beneﬁt hospitals preparing for care under bundled payments
by serving as external cost benchmarking, researchers working to
understand the costs associated with adverse events and increased
comorbidity in TJR, and clinicians developing specialized care al-
gorithms for patients dependent on their expected care pathway.Acknowledgments
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Appendix A
Codes Used for Patient Selection.
Cohort Selection Criteria Code Type* Code Description
Primary unilateral
TKA
Inclusion ICD9 Proc 81.54 Total knee arthroplasty
Exclusion ICD9 Proc 81.54 Total knee arthroplasty
Exclusion ICD9 Proc 81.51 Total hip arthroplasty
Exclusion ICD9 Proc 80.06 Arthrotomy for removal of prosthesis knee
Exclusion ICD9 Proc 81.55 Revision of knee arthroplasty, not otherwise speciﬁed
Exclusion ICD9 Proc 00.80-00.84 Revision of knee arthroplasty
Exclusion CPT 27486 Revision of total knee arthroplasty, with or without allograft; 1 component
Exclusion CPT 27487 Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial
component
Exclusion CPT 27488 Removal of prosthesis, including total knee prosthesis, methylmethacrylate with or
without insertion of spacer, knee
Revision TKA Inclusion ICD9 Proc 80.06 Arthrotomy for removal of prosthesis knee
Inclusion ICD9 Proc 81.55 Revision of knee arthroplasty, not otherwise speciﬁed
Inclusion ICD9 Proc 00.80-00.84 Revision of knee arthroplasty
Inclusion CPT 27486 Revision of total knee arthroplasty, with or without allograft; 1 component
Inclusion CPT 27487 Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial
component
Exclusion ICD9 Proc 81.51 Total hip arthroplasty
Primary THA Inclusion ICD9 Proc 81.51 Total hip arthroplasty
Exclusion ICD9 Proc 81.54 Total knee arthroplasty
Exclusion ICD9 Proc 81.53 Revision of hip arthroplasty, not otherwise speciﬁed
Exclusion ICD9 Proc 00.70-00.73 Revision of hip arthroplasty
Exclusion CPT 27091 Removal of hip prosthesis; complicated, including total hip prosthesis,
methylmethacrylate with or without insertion of spacer
Exclusion CPT 27134 Revision of total hip arthroplasty; both components, with or without autograft or
allograft
Revision THA Inclusion ICD9 Proc 81.53 Revision of hip arthroplasty, not otherwise speciﬁed
Inclusion ICD9 Proc 00.70-00.73 Revision of hip arthroplasty
Inclusion CPT 27091 Removal of hip prosthesis; complicated, including total hip prosthesis,
methylmethacrylate with or without insertion of spacer
Inclusion CPT 27134 Revision of total hip arthroplasty; both components, with or without autograft or
allograft
Exclusion ICD9 Proc 81.54 Total knee arthroplasty
All Exclusion ICD9 Dx 733.10 Fracture unspeciﬁed site
All Exclusion ICD9 Dx 733.14 Fracture of femur
All Exclusion ICD9 Dx 733.15 Fracture of other part of femur
All Exclusion ICD9 Dx 733.16 Fracture of tibia or ﬁbula
All Exclusion ICD9 Dx 808 Fracture of pelvis
All Exclusion ICD9 Dx 820 Fracture of neck of femur
All Exclusion ICD9 Dx 821 Fracture other parts of femur
All Exclusion ICD9 Dx 827 Other fractures of lower limb
All Exclusion ICD9 Dx 828 Multiple fractures both lower limb
* CPT, Current Procedural Technology; ICD9 Dx, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, Diagnosis Codes; ICD9 Proc, International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, Procedure Codes.
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Appendix B
Codes Used for Study Measure Creation.
Study Measure Group Code Type* Code Description
Hematoma/seroma ICD9 Dx 998.1 Hemorrhage or hematoma complicating a procedure not elsewhere classiﬁed
Hematoma/seroma ICD9 Dx 998.11 Hemorrhage complicating a procedure
Hematoma/seroma ICD9 Dx 998.12 Hematoma complicating a procedure
Hematoma/seroma ICD9 Dx 998.13 Seroma complicating a procedure
Hematoma/seroma ICD9 Proc 39.41 Control of hemorrhage, not otherwise speciﬁed
Postoperative infection ICD9 Proc 996.60 Infection and inﬂammatory reaction due to unspeciﬁed device, implant, and graft
Postoperative infection ICD9 Proc 996.66 Infection and inﬂammatory reaction due to internal joint prosthesis
Postoperative infection ICD9 Proc 996.67 Infection and inﬂammatory reaction due to other internal orthopedic device, implant,
and graft
Postoperative infection ICD9 Proc 996.69 Infection and inﬂammatory reaction due to other internal prosthetic device, implant,
and graft
Postoperative infection ICD9 Dx 038.x Septicemia
Postoperative infection ICD9 Dx 730.90 Unspeciﬁed infection of bone, site unspeciﬁed
Postoperative infection ICD9 Dx 730.95 Unspeciﬁed infection of bone, pelvic region and thigh
Postoperative infection ICD9 Dx 730.96 Unspeciﬁed infection of bone, lower leg
Postoperative infection ICD9 Dx 730.98 Unspeciﬁed infection of bone, other speciﬁed sites
Postoperative infection ICD9 Dx 730.99 Unspeciﬁed infection of bone, multiple sites
Postoperative infection ICD9 Dx 998.51-.59 Postoperative infection not elsewhere classiﬁed
Postoperative infection ICD9 Dx 999.31-.39 Other infection due to medical care not elsewhere classiﬁed
Wound disruption ICD9 Dx 998.31 Disruption of internal operation (surgical) wound
Wound disruption ICD9 Dx 998.51 Infected postoperative seroma
Wound disruption ICD9 Dx 998.32 Disruption of external operation (surgical) wound
Wound disruption ICD9 Dx 998.6 Persistent postoperative ﬁstula
Wound disruption ICD9 Dx 998.83 Nonhealing surgical wound
Dislocation of joint ICD9 Dx 996.42 Dislocation of prosthetic joint
Neurologic ICD9 Dx 997.00 Nervous system complication, unspeciﬁed
Neurologic ICD9 Dx 997.01 Central nervous system complication
Neurologic ICD9 Dx 997.02 Iatrogenic cerebrovascular infarction or hemorrhage
Neurologic ICD9 Dx 997.09 Other nervous system complications
Pulmonary embolism ICD9 Dx 415.0 Acute cor pulmonale
Pulmonary embolism ICD9 Dx 415.1 Pulmonary embolism and infarction
Pulmonary embolism ICD9 Dx 415.11 Iatrogenic pulmonary embolism and infarction
Pulmonary embolism ICD9 Dx 415.12 Septic pulmonary embolism
Pulmonary embolism ICD9 Dx 415.13 Saddle embolus of pulmonary artery
Pulmonary embolism ICD9 Dx 415.19 Other pulmonary embolism and infarction
Phlebitis and thrombophlebitis ICD9 Dx 451.0 Phlebitis and thrombophlebitis of superﬁcial vessels of lower extremities
Phlebitis and thrombophlebitis ICD9 Dx 451.1 Phlebitis and thrombophlebitis of deep veins of lower extremities
Phlebitis and thrombophlebitis ICD9 Dx 451.11 Phlebitis and thrombophlebitis of femoral vein (deep) (superﬁcial)
Phlebitis and thrombophlebitis ICD9 Dx 451.19 Phlebitis and thrombophlebitis of deep veins of lower extremities, other
Phlebitis and thrombophlebitis ICD9 Dx 451.2 Phlebitis and thrombophlebitis of lower extremities, unspeciﬁed
Phlebitis and thrombophlebitis ICD9 Dx 451.8 Phlebitis and thrombophlebitis of other sites
Phlebitis and thrombophlebitis ICD9 Dx 451.81 Phlebitis and thrombophlebitis of iliac vein
Phlebitis and thrombophlebitis ICD9 Dx 451.82 Phlebitis and thrombophlebitis of superﬁcial veins of upper extremities
Phlebitis and thrombophlebitis ICD9 Dx 451.83 Phlebitis and thrombophlebitis of deep veins of upper extremities
Phlebitis and thrombophlebitis ICD9 Dx 451.84 Phlebitis and thrombophlebitis of upper extremities, unspeciﬁed
Phlebitis and thrombophlebitis ICD9 Dx 451.89 Phlebitis and thrombophlebitis of other sites
Phlebitis and thrombophlebitis ICD9 Dx 451.9 Phlebitis and thrombophlebitis of unspeciﬁed site
Venous embolism ICD9 Dx 453 Other venous embolism and thrombosis
Venous embolism ICD9 Dx 453.1 Thrombophlebitis migrans
Venous embolism ICD9 Dx 453.2 Other venous embolism and thrombosis of inferior vena cava
Venous embolism ICD9 Dx 453.3 Other venous embolism and thrombosis of renal vein
Venous embolism ICD9 Dx 453.4 Acute venous embolism and thrombosis of deep vessels of lower extremity
Venous embolism ICD9 Dx 453.5 Chronic venous embolism and thrombosis of deep vessels of lower extremity
Venous embolism ICD9 Dx 453.6 Venous embolism and thrombosis of superﬁcial vessels of lower extremity
Venous embolism ICD9 Dx 453.7 Chronic venous embolism and thrombosis of other speciﬁed vessels
Venous embolism ICD9 Dx 453.8 Acute venous embolism and thrombosis of other speciﬁed veins
Venous embolism ICD9 Dx 453.9 Other venous embolism and thrombosis of unspeciﬁed site
Pulmonary ICD9 Dx 518.5 Pulmonary insufﬁciency following trauma and surgery
Pulmonary ICD9 Dx 518.81 Acute respiratory failure
Pulmonary ICD9 Dx 518.82 Other pulmonary insufﬁciency, not elsewhere classiﬁed
Pulmonary ICD9 Dx 518.83 Chronic respiratory failure
Pulmonary ICD9 Dx 518.84 Acute and chronic respiratory failure
Pulmonary ICD9 Dx 997.3 Respiratory complications not elsewhere classiﬁed
Cardiac ICD9 Dx 997.1 Cardiac complications, not elsewhere classiﬁed
Cardiac ICD9 Dx 410 Acute myocardial infarction
Urinary and renal ICD9 Dx 580 Acute glomerulonephritis
Urinary and renal ICD9 Dx 584 Acute kidney failure
Urinary and renal ICD9 Dx 997.5 Urinary complications, not elsewhere classiﬁed
Pneumonia ICD9 Dx 481 Pneumococcal pneumonia
Pneumonia ICD9 Dx 482 Other bacterial pneumonia
Pneumonia ICD9 Dx 485 Bronchopneumonia, organism unspeciﬁed
Pneumonia ICD9 Dx 486 Pneumonia, organism unspeciﬁed
Transfusion-related complication ICD9 Dx 518.7 Transfusion-related acute lung injury
(continued on next page)
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Appendix B (continued )
Study Measure Group Code Type* Code Description
Transfusion-related complication ICD9 Dx 518.8 Other diseases of lung (acute respiratory failure, other pulmonary insufﬁciency, acute
and chronic respiratory failure, other diseases of lung not otherwise speciﬁed)
Transfusion-related complication ICD9 Dx 999.4 Anaphylactic reaction to serum
Transfusion-related complication ICD9 Dx 999.5 Other serum reaction not elsewhere classiﬁed
Transfusion-related complication ICD9 Dx 999.6 ABO incompatibility reaction due to transfusion of blood or blood products
Transfusion-related complication ICD9 Dx 999.7 Rh incompatibility reaction not elsewhere classiﬁed
Transfusion-related complication ICD9 Dx 999.8 Other and unspeciﬁed transfusion reaction not elsewhere classiﬁed
Transfusion allogeneic CPT 36430 Transfusion, blood or blood components
Transfusion allogeneic HCPCS P9010 Blood (whole), for transfusion, per unit
Transfusion allogeneic HCPCS P9011 Blood, split unit
Transfusion allogeneic ICD9 Dx V582 Blood transfusion, without reported diagnosis
Transfusion allogeneic ICD9 Proc 9903 Other transfusion of whole blood
Transfusion allogeneic ICD9 Proc 9904 Transfusion of packed cells
Transfusion autologous ICD9 Proc 9900 Perioperative autologous transfusion of whole blood or blood components
Transfusion autologous ICD9 Proc 9901 Exchange transfusion
Transfusion autologous ICD9 Proc 9902 Transfusion of previously collected autologous blood
* CPT, Current Procedural Technology; ICD9 Dx, International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, Diagnosis Codes; ICD9 Proc, International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, Procedure Codes; HCPCS, Healthcare Common Procedure Coding System.
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